DOCSLIB.ORG

Kalbe Farma Tbk

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Kalbe Farma Tbk Company Update Unaudited YTD September 2020 October 2020 Forward Looking Statement This presentation has been prepared for informational purposes only by PT Kalbe Farma Tbk. (“Kalbe” or the “Company”). This presentation has been prepared solely for use in connection with the release of 30 September 2020 unaudited results of the Company. The information contained in this presentation has not been independently verified. No representation, warranty or undertaking, express or implied, is made as to, and no reliance should be placed on, the fairness, accuracy, completeness or correctness of the information or the opinions contained herein. None of the Company or any of their respective affiliates, and their respective commissioners, directors and employees, advisors or representatives shall have any liability whatsoever (in negligence or otherwise) for any loss howsoever arising from any use of this presentation or its contents or otherwise arising in connection with the presentation. Any decision to purchase or subscribe for securities of the Company should not be made on the basis of the information contained in this presentation. The presentation is not an offer of securities for sale in the United States. Securities may not be offered or sold in the United States absent registration or an exemption from registration. This presentation and its contents are confidential unless they are or become generally available as public information in accordance with prevailing laws and regulations (other than as a result of a disclosure by you) and must not be distributed, published or reproduced (in whole or in part) or disclosed by recipients to any other person. This presentation does not constitute a recommendation regarding the securities of the Company. This presentation, including the information and opinions contained herein, is provided as of the date of this presentation and is subject to change without notice, including change as a result of the issuance of 30 September 2020 unaudited results of the Company . This presentation includes "forward-looking statements". These statements contain the words "anticipate", "believe", "intend", estimate", "expect" and words of similar meaning. All statements other than statements of historical facts included in this presentation, including, without limitation, those regarding the Company's financial position, business strategy, plans and objectives of management for future operations (including development plans, objectives relating to the Company's products and services and anticipated product launches) are forward-looking statements. Such forward-looking statements are based on numerous assumptions regarding the Company's present and future business strategies and the environment in which the Company will operate in the future. These forward-looking statements speak only as at the date of this presentation. The Company expressly disclaims any obligation or reflection of any change in the Company's expectations with regard thereto, or any change in events, conditions or circumstances on which any statement is based. Market data and certain industry forecasts used in this presentation were obtained from market research, publicly available information and industry publications which have not been independently verified, and no representation is made as to the accuracy of such information. 2 Table of Content 04 Corporate Overview 07 Market Overview 13 Business Overview 28 Financial Overview 35 Strategies & Outlook 2020 39 Appendix 3 PT Kalbe Farma Tbk PTFarma Kalbe Section 1 Corporate Overview 4 Corporate Overview Established in 1966 and headquartered in Jakarta A public company since 1991 and listed in the Indonesia Stock Exchange – free float stocks (public) 42.96%* The largest publicly-listed pharmaceuticals company in Southeast Asia – market cap 4.9 billion USD* Sales breakdown by segment and by geographical location for end of September 2020 is as follows: PRESCRIPTION 22% PHARMACEUTICALS 5% CONSUMER 17% HEALTH export NUTRITIONALS 29% 95% DISTRIBUTION & domestic LOGISTICS 32% * As of September 2020 5 Corporate Overview Inception and Entrepreneurial Enhanced Focus Regionalization and Strengthening Portfolio Driven Expansion and Consolidation 2006–2019 1966–1995 1996–2005 2005: 2012: 1981: Forming joint 2010: ♦ Generic production Spin-off the venture companies, Disposed of Kageo Igar Jaya facility came on 2016: 2006: distribution 1994: PT Kalbe Morinaga Established a joint venture stream 2014: Forming a 2018: business to 1989: Entered Indonesia and Scale company, Asiawide Kalbe ♦ Acquired PT Hale Completion joint venture Forming a PT Enseval Igar Jaya energy Orange Kalbe through Philippines Inc. International of Kalbe’s joint venture 1966: company, PT due to and drink Limited mergers Inaugurated Panca Sradha ♦ Established a joint oncology Medika company, PT Company government Dankos business Consolidation of and Kalbe as our Corporate venture company PT factory Innolab Sains founded Komunika regulation IPOs EPMT IPO Kalbe Group acquisitions Values Kalbe Milko Indonesia Teknologi Internasional 1966 1977 1981 1985 1989 1991 1993 1994 1995 1997 2005 2006 2007 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 1977: 1985: 1991: 1993: 1995: 1997: 2007: 2011: 2013: 2015: 2017: 2019: Strengthen Expansion to Kalbe Strengthening Disposed Disposed of Launch of new EPMT Rights Cancellation Forming Completed Groundbre pharma consumer Farma nutritionals of 50% of Kalbe’s remaining corporate logo as Issue to finance of the joint construction aking business by health IPO business by food 50% ownership in part of expansion Company’s venture of Biosimilar Kalbe establishing through acquiring business PT Bukit Manikam transformation Increased Treasury companies, Factory Myanmar Dankos Lab acquisition of Sanghiang (PT Bukit Sakti to Arnotts process dividend Stocks of PT Kalbe Factory Bintang Perkasa and Manikam Disposed glass Products entered payout ratio to 7.7% Blackmores Toedjoe and consolidating Sakti) to packaging division every ASEAN 50% Nutrition in pharma nutritional Arnotts to Schott countries (except and PT through business to Acquired Woods Laos) Kalbe- Hexpharm Sanghiang Peppermint brand Opening of the Stem Genexine Jaya Perkasa Acquired 80% of Cell and Cancer Biologics acquisition Saka Farma Institute Implementation of end-to-end supply chain management Integrated information technology systems 6 IMMUNOMODULATOR INNOVATION Tbk PTFarma Kalbe HERBAL FROM INDONESIA Section 2 Combination of Indonesia 4 traditional herbal active for antivirus, anti inflammatory and immunomodulator Market Overview Anti inflammatory Anti inflammatory & Improve 7 Respiratory System Macro Overview Covid -19 Update KALBE UPDATE INDONESIA GOVERNMENT POLICY • Since March 2020, Kalbe launched an initiative called “Together. We Overcome Covid-19” in • Health Protocol about COVID-19 published amount of IDR 25 billion to support all hospitals, on 31 March 2020. clinic, patients, institutions, volunteers, public and • Minister of Health Regulation number 9 year 2020 our government by providing free disposable regarding Pedoman Pembatasan Sosial Berskala Besar (Large protective clothing medical use, surgical mask, Scale Social Restriction) ; which is a derivative of Government rapid test, medicine, vitamins and supplement. Regulation (PP) number 21 year 2020 regarding the Framework for the Acceleration in Handling Corona Virus Disease 2019 • On April 2020, Kalbe through Kalgen-Innolab (Covid-19). Clinical Laboratory provides Covid-19 examination • Regulation of the Minister of Transportation Number PM 25 services using Reverse Transcription Polymerase year 2020 regarding transportation control during the 1441H Chain Reaction (RT-PCR) to support the Idul Fitri homecoming in order to prevent the spread of Corona government. Virus Disease 2019 (COVID-19). • On May 2020, Kalbe signed a MoU with Genexine, • Regulation of the Minister of Finance Number 44 / PMK.03 / 2020 about Tax Incentives for Taxpayers Affected by the Corona Inc., a biological drug company from South Korea to Virus Disease 2019 develop a vaccine (GX-19) for the new corona virus • Various Subsidy from Government to Informal Workers and or Covid-19. Low – Midlle Income Households •On June 2020, Kalbe took part in a clinical trial using herbal ingredient in collaboration with Ministry of Research and Technology, local university, research institution, and health association. • On October 2020, Indian Pharmaceutical major Hetero’s subsidiary ‘PT. Amarox Pharma Global’, in collaboration with Kalbe, becomes the 1st company to launch Covifor (Remdesivir) in Indonesia. Macro Overview Covid -19 Update Clinical Trial on Herbal Products Launching Covifor (Remdesivir) Tested Products : Clinical trial location: in Indonesia RS. Wisma Atlet Kalbe in collaboration with PT. Amarox Pharma Global launched the antiviral drug Covifor (Remdesivir) for Covid-19 treatment in Indonesia. Leveraging Kalbe's capabilities and nationwide marketing and distribution infrastructure, this collaboration will enable faster and wider access of the drug for COVID-19 patients In Collaboration with: throughout Indonesia. COVID-19 DNA Vaccine Candidate DNA Vaccine advantages : Simple and cost Easy and rapid effective development manufacturing Kalbe and Genexine has agreed to conduct 2nd phase of clinical trials in Indonesia, this development of DNA vaccines will be carried Highly stable and out by the consortium of Genexine, Binex, No risk for infection the International Vaccine
Load more

Recommended publications
  • Pasar Farmasi Indonesia
    Company Update Audited FY December 2013 March 2014 Forward Looking Statement This presentation has been prepared for informational purposes only by PT Kalbe Farma Tbk. (“Kalbe” or the “Company”). This presentation has been prepared solely for use in connection with the release of 31 December 2013 audited results of the Company. The information contained in this presentation has not been independently verified. No representation, warranty or undertaking, express or implied, is made as to, and no reliance should be placed on, the fairness, accuracy, completeness or correctness of the information or the opinions contained herein. None of the Company or any of their respective affiliates, and their respective commissioners, directors and employees, advisors or representatives shall have any liability whatsoever (in negligence or otherwise) for any loss howsoever arising from any use of this presentation or its contents or otherwise arising in connection with the presentation. Any decision to purchase or subscribe for securities of the Company should not be made on the basis of the information contained in this presentation. The presentation is not an offer of securities for sale in the United States. Securities may not be offered or sold in the United States absent registration or an exemption from registration. This presentation and its contents are confidential unless they are or become generally available as public information in accordance with prevailing laws and regulations (other than as a result of a disclosure by you) and must not be distributed, published or reproduced (in whole or in part) or disclosed by recipients to any other person. This presentation does not constitute a recommendation regarding the securities of the Company.
    [Show full text]
  • Pasar Farmasi Indonesia
    Not all collagen is the same, it’s time to choose the right one Company Update Unaudited YTD September 2014 October 2014 Forward Looking Statement This presentation has been prepared for informational purposes only by PT Kalbe Farma Tbk. (“Kalbe” or the “Company”). This presentation has been prepared solely for use in connection with the release of 30 September 2014 unaudited results of the Company. The information contained in this presentation has not been independently verified. No representation, warranty or undertaking, express or implied, is made as to, and no reliance should be placed on, the fairness, accuracy, completeness or correctness of the information or the opinions contained herein. None of the Company or any of their respective affiliates, and their respective commissioners, directors and employees, advisors or representatives shall have any liability whatsoever (in negligence or otherwise) for any loss howsoever arising from any use of this presentation or its contents or otherwise arising in connection with the presentation. Any decision to purchase or subscribe for securities of the Company should not be made on the basis of the information contained in this presentation. The presentation is not an offer of securities for sale in the United States. Securities may not be offered or sold in the United States absent registration or an exemption from registration. This presentation and its contents are confidential unless they are or become generally available as public information in accordance with prevailing laws and regulations (other than as a result of a disclosure by you) and must not be distributed, published or reproduced (in whole or in part) or disclosed by recipients to any other person.
    [Show full text]
  • PT Kalbe Farma Tbk. Dan Entitas Anaknya/And Its Subsidiaries
    PT Kalbe Farma Tbk. dan Entitas Anaknya/ and its Subsidiaries Laporan keuangan konsolidasian tanggal 30 Juni 2019 dan untuk periode yang berakhir pada tanggal tersebut (Belum Diaudit)/ Consolidated financial statements as of June 30, 2019 and for the period then ended (Unaudited) The original consolidated financial statements included herein are in the Indonesian language. PT KALBE FARMA Tbk. DAN ENTITAS ANAK NYA PT KALBE FARMA Tbk. AND ITS SUBSIDIARIES LAPORAN KEUANGAN KONSOLIDASIAN CONSOLIDATED FINANCIAL STATEMENTS TANGGAL 30 JUNI 2019 DAN AS OF JUNE 30, 2019 AND UNTUK PERIODE YANG BERAKHIR PADA FOR THE PERIOD THEN ENDED (UNAUDITED) TANGGAL TERSEBUT (BELUM DIAUDIT) Daftar Isi Table of Contents Halaman/ Page Laporan Posisi Keuangan Konsolidasian ......................... 1-3 ............ Consolidated Statement of Financial Position Laporan Laba Rugi dan Penghasilan Consolidated Statement of Profit or Loss Komprehensif Lain Konsolidasian ............................. 4-5 ..................... and Other Comprehensive Income Laporan Perubahan Ekuitas Konsolidasian ..................... 6 ........... Consolidated Statement of Changes in Equity Laporan Arus Kas Konsolidasian ..................................... 7-8 ..................... Consolidated Statement of Cash Flows Catatan Atas Laporan Keuangan Konsolidasian .............. 9-139 ....... Notes to the Consolidated Financial Statements *************************** g PT KALBE FARMA Tbk. DAN ENTITAS ANAKNYA PT KALBE FARMA Tbk. AND ITS SUBSIDIARIES LAPORAN POSISI KEUANGAN KONSOLIDASIAN CONSOLIDATED
    [Show full text]
  • Kalbe Farma (KLBF
    Company Update Indonesia 11 November 2019 Healthcare | Pharmaceuticals Kalbe Farma (KLBF IJ) Buy (Maintained) Ground Checks: Investment In The Future; BUY Target Price (Return) IDR2,000 (+25%) Price: IDR1,595 Market Cap: USD5,309bn Avg Daily Turnover (IDR/USD) 49bn/3.5m Maintain BUY and IDR2,000 TP, 25% upside plus c.2% yield. We recently Analysts visited the Kalbio Global Medika (KGM) production facility in Cikarang, West Java. KGM, KLBF’s subsidiary, specialises in biosimilar products, in Jessica Pratiwi partnership with South Korean biotechnology R&D company, Genexine Inc. +6221 5093 9845 The facility has a land area of 11,000 sqm and 195 employees. The site visit [email protected] was hosted by Daniel Iskandar Wirawan (site head) and Fahrizal Nugraha (QC manager) from KGM, and Megawati Purnama and Marcella Cloudia (KLBF investor relations team). Michael W Setjoadi Higher biosimilar sales to support declining pharma margins. Competition +6221 5093 9844 in the biosimilar market is not as strong as in generic drugs given the high [email protected] development costs and production complexity (c.2 months/batch). The two local competitors are Combiphar Dong-A and Daewoong Infion. EBIT margin Share Performance (%) in this segment is also much more attractive at 23-25% vs 8-10% for unbranded YTD 1m 3m 6m 12m generics. Absolute 4.3 (2.8) 10.8 5.7 14.0 Currently, 90% of KLBF’s biosimilars, mainly the Hemapo drug (c.3,000 Relative 4.7 (5.5) 11.5 7.8 10.2 units/year), are for National Social Health Insurance (JKN) patients.
    [Show full text]
  • Company Performance Company Performance
    Company Performance YTD September 2008 Contents Part 1 Kalbe at a Glance Part 2 Pharmaceutical Industry Overview Part 3 Business Overview A. Prescription Pharmaceuticals B. Nutritionals C. Consumer Health D. Distribution and Packaging Part 4 Operational Overview Part 5 Growth Drivers Part 6 Financial Overview Part 7 Recent Activities PtPart 8 FtFuture OtlkOutlook 2 Part 1 Kalbe at a Glance 3 Comppyggany Highlights Largest Publicly-Listed ♦ More than 42-year old pharmaceutical company with long track record of profitable growth. Pharmaceutical ♦ After the merger with PT Dankos Laboratories Tbk. and PT Enseval effective on December 16, Company in Southeast 2005, Kalbe has become the largest publicly-listed pharmaceutical company in Southeast Asia with approximately US$ 1 billion market capitalization in the past year. Asia 3 ♦ Lttltif2Large target population of 235 million in In dones ia, an d 570 million in Sou theas t As ia. Substantial Market ♦ OTC and prescription pharma in the Indonesian and Southeast Asian markets expected to grow Opportunity annually at 10% and 13% respectively over the next several years. ♦ The market leader in Indonesian prescription pharma market with 13% market share as well as a Market Leading leader in consumer health market with 16% OTC market share, 9% share in nutrition market and Positions in Indonesia 30% in energy drink market for the first semester in year 2008. ♦ Unrivaled health distribution network which directlyyy and indirectly covers more than 1 million outlets. Strong, Diversified, ♦ Consumer health portfolio which includes 13 market leading OTC brands in 7 main therapeutic categories, the market leading brand in pregnant nutrition and clinical foods, and the leading energy High Growth Product drink in Indonesia.
    [Show full text]
  • PT Kalbe Farma Tbk
    20, AVENUE APPIA – CH-1211 GENEVA 27 – SWITZERLAND – TEL CENTRAL +41 22 791 2111 – FAX CENTRAL +41 22 791 3111 – WWW.WHO.INT Prequalification Team Inspection services WHO PUBLIC INSPECTION REPORT of the FPP manufacturer Part 1 General information Manufacturers details Company information Name of PT. Kalbe Farma Tbk. manufacturer and Delta Silicon Industrial Park address Jl. M. H. Thamrin Blok A3-1, Lippo Cikarang, Bekasi 17550, Indonesia. PO. BOX 371, Bekasi 17037, Indonesia Phone 62-21-89907333 (24 hours) Fax 62-21-8972874 GPS Coordinate ; 6°19’15.4175” South, 107°7’0.1182” East Corporate KALBE Building address of Jl. Let.Jend. Suprapto Kav.4, Central Jakarta 10510 manufacturer PO BOX 3105 JAK, Jakarta , Indonesia Phone 62-21-42873888 – 89 Fax 62-21-42873680 Inspected site Address of As above inspected manufacturing site Unit / block / Production line 8A workshop number WHOPIR PT.Kalbe Farma Tbk, Indonesia 24, 25 and 28 May 2018 This inspection report is the property of the WHO Contact: [email protected] Page 1 of 16 20, AVENUE APPIA – CH-1211 GENEVA 27 – SWITZERLAND – TEL CENTRAL +41 22 791 2111 – FAX CENTRAL +41 22 791 3111 – WWW.WHO.INT Manufacturing • CPOB Cairan oral non beta laktam (GMP non beta lactam oral liquid) license number Certificate Number: 4655/CPOB/A/XII/15 License Number: HK.07.IF/V/109/11 License Date: 18 May 2011 Valid until: 31 Dec 2020 • CPOB Kapsul keras non beta laktam (GMP non beta lactam hard capsule) Certificate Number: 4654/CPOB/A/XII/15 License Number: HK.07.IF/V/109/11 License Date: 18 May 2011 Valid
    [Show full text]
  • Evogenix and CSL Partner on Antibodies • Minomic's Business • Japan's Bioventures Today
    www.asiabiotech.com Industry Watch Australia EvoGenix and CSL Partner on Antibodies ntibody therapeutics company, EvoGenix Ltd, had entered a Technology Collaboration agreement with CSL Ltd. EvoGenix will apply its proprietary Atechnologies to antibody products selected by CSL from its pipeline. The collaboration is designed to generate superior antibodies that are more effective as human therapeutics. CSL will have the right to commercialize the products. EvoGenix will receive royalty payments as therapeutics emerging from the collaboration reach the market. Under the terms of the agreement, EvoGenix will receive research payments to carry out work on CSL’s products. Each project carries a success payment for the achievement of project goals, as well as milestone payments as the product advances through the subsequent stages of clinical testing and regulatory approvals. The agreement marks the growing interest of Australian healthcare companies in the dynamic antibody sector, which is seen as the source of many of the future blockbuster drugs. Dr Andrew Cuthbertson, CSL’s Chief Scientific Officer commented, “CSL has identified antibody therapeutics as a focus of its expanding product pipeline. We are delighted to access key technologies which can accelerate development of our antibodies as effective treatments through this collaboration with EvoGenix. “ Dr Rob Crombie, VP for Business Development with EvoGenix, noted “We are looking forward to a highly productive relationship in developing these projects with CSL. As Australia’s leading healthcare company, and with their track record of success in taking biopharmaceuticals to the market, CSL is ideally placed to accelerate antibodies emerging from the collaboration through to becoming successful products.” This is the second major collaboration EvoGenix has made to exploit its proprietary antibody development technologies.
    [Show full text]
  • PT KALBE FARMA Tbk. DAN ANAK PERUSAHAAN PT KALBE FARMA Tbk
    PT Kalbe Farma Tbk. Dan PT Kalbe Farma Tbk. And Anak Perusahaan Subsidiaries Laporan Keuangan Konsolidasi Consolidated Financial Statements (Belum Diaudit) (Unaudited) Untuk Sembilan Bulan Yang Berakhir Pada For The Nine Months Ended Tanggal-tanggal 30 September 2006 Dan 2005 September 30, 2006 And 2005 (Setelah Penggabungan Usaha) (After Merger) (Mata Uang Indonesia) (Indonesian Currency) Meningkatkan Kesehatan untuk Kehidupan yang Lebih Baik To Improve Health for A Better Life The original consolidated financial statements included herein are in Indonesian language. PT KALBE FARMA Tbk. DAN ANAK PERUSAHAAN PT KALBE FARMA Tbk. AND SUBSIDIARIES LAPORAN KEUANGAN KONSOLIDASI CONSOLIDATED FINANCIAL STATEMENTS (BELUM DIAUDIT) (UNAUDITED) SEMBILAN BULAN YANG BERAKHIR PADA NINE MONTHS ENDED TANGGAL-TANGGAL SEPTEMBER 30, 2006 AND 2005 30 SEPTEMBER 2006 DAN 2005 (AFTER MERGER) (SETELAH PENGGABUNGAN USAHA) Daftar Isi Table of Contents Halaman/ Page Neraca Konsolidasi 1-3 Consolidated Balance Sheets Laporan Laba Rugi Konsolidasi 4-5 Consolidated Statements of Income Consolidated Statements of Changes in Laporan Perubahan Ekuitas Konsolidasi 6 Shareholders’ Equity Laporan Arus Kas Konsolidasi 7-8 Consolidated Statements of Cash Flows Catatan atas Laporan Keuangan Konsolidasi 9-87 Notes to the Consolidated Financial Statements *************************** The original consolidated financial statements included herein are in Indonesian language. PT KALBE FARMA Tbk. DAN ANAK PERUSAHAAN PT KALBE FARMA Tbk. AND SUBSIDIARIES NERACA KONSOLIDASI CONSOLIDATED
    [Show full text]
  • Cygenics Asian Healthcare Presence Expanded in Indonesia
    www.asiabiotech.com Industry Watch Australia CyGenics Asian Healthcare Presence Expanded in Indonesia eading tissue and cord blood banking company CyGenics Ltd has announced Indonesia’s leading pharma company, Kalbe Farma, has taken a 49% stake in Lits cord blood banking subsidiary, CordLife Indonesia. CordLife Indonesia will establish new cord blood processing and storage facility to be fully operational by early 2007. CordLife Indonesia will launch expanded marketing and sales of cord blood banking business later this year. This is a further, important step in CyGenics strategy of focusing on its core business of tissue and cord blood banking, and greatly strengthens its presence in a large and important market in the Asian region. The expansion of the Indonesian operations is in line with CyGenics’ focus on revenue generating cord blood banking services and on establishing a sound presence in all major markets in the Asian region. Kalbe Farma is the largest publicly-listed pharmaceutical company in Southeast Asia, with a market capitalisation of approximately US$1.5 billion and US$600 million in annual revenue in 2005. Kalbe Farma has over 12,000 employees, which includes a sales force of 6,000 covering 80% of the Indonesian consumer and hospital health market. Further, it is the dominant supplier to the Indonesian prescription pharmaceutical market. CordLife Indonesia has been in operation since December 2003. The cord blood units have been couriered to Singapore, for processing and storage at the company’s AABB-accredited facility. The volume of business in Indonesia has grown to the extent that the operations now require a cord blood processing and storage facility in the country.
    [Show full text]
  • YS% ,Xld M%Cd;Dka;S%L Iudcjd§ Ckrcfha .Eiü M;%H W;S Úfyi the Gazette of the Democratic Socialist Republic of Sri Lanka EXTRAORDINARY
    YS% ,xld m%cd;dka;s%l iudcjd§ ckrcfha .eiÜ m;%h w;s úfYI The Gazette of the Democratic Socialist Republic of Sri Lanka EXTRAORDINARY wxl 2144$20 - 2019 Tlaf;dan¾ ui 09 jeks nodod - 2019'10'09 No. 2144/20 - WEDNESDAY, OCTOBER 9, 2019 (Published by Authority) PART I : SECTION (I) — GENERAL Government Notifi cations Order No. 01 NATIONAL MEDICINES REGULATORY AUTHORITY ACT, NO. 5 OF 2015 Order under section 60 (2) BY VIRTUE of the powers vested in me by section 60 (2) of the National Medicines Regulatory Authority Act, No. 5 of 2015, I, Prof. Asita De Silva, Chairman of the National Medicines Regulatory Authority, do by this Order, inform the public that the medicines specifi ed in the Schedules here to have been registered with the National Medicines Regulatory Authority. Prof. ASITA DE SILVA Chairman, (For and on behalf of) National Medicines Regulatory Authority Colombo August 8, 2019 1A—PG 4679 - 257 (10/2019) This Gazette Extraordinary can be downloaded from www.documents.gov.lk 2 SCHEDULE - I P ART I:S COLUMN-I COLUMN-II COLUMN- COLUMN-IV COLUMN-V COLUMN- COL- COL- EC III VI UMN-VII UMN-VIII I . (I) - GAZETTE EXTRAORDINARY OF THE DEMOCRATIC SOCIALIST REPUBLIC OF SRI LANKA -09.10.2019 REPUBLICOFSRILANKA SOCIALIST THE DEMOCRATIC OF . (I)-GAZETTEEXTRAORDINARY fldgi (^ Offi cial Name Brand Name Dosage Importer Manufacturer Man- Issue Reg. Form Name Country Date Type 1 BENZALKONIUM CHLORIDE,CETRIMID 0.01%,0.2% DRAPOLENE CREAM GlaxoSmithkiline Glaxo Smithkiline POLAND 24-Mar- Full I & fPoh - YS% ,xld m%cd;dka;s%l iudcjd§ ckrcfha w;s úfYI .eiÜm;%h-2019'10'09
    [Show full text]
  • Equity SNAPSHOT Tuesday, August 24, 2021
    Equity SNAPSHOT Tuesday, August 24, 2021 FROM EQUITY REPORT KEY INDEX KEY INDEX Chg Ytd Vol Chg Ytd Vol Elang Mahkota Teknologi: The E-agle has landed Close Close (EMTK.IJ IDR 2,030 BUY TP. IDR 3,000) (%) (%) (US$ m) (%) (%) (US$ m) EMTK is Indonesia’s own Softbank and Alibaba, supported by its cash Asean - 5 Asean - 5 machine SCMA as the source of funds. EMTK allocate the dividend Indonesia 6.110 1,3 2,2 793 Indonesia 6,134 0.1 (1.0) 318 for tech investments, the most notable is, BUKA being their success Thailand 1.582 1,9 9,2 3.458 Thailand 1,568 (0.1) 0.2 1,454 story whereby the estimated ROI is more than 12x, and from the Philippines 6.592 (0,6) (7,7) 103 Philippines 7,855 (0.3) 5.2 87 recent huge IPO. EMTK recently did an IDR9.3tn NPRI, with some Malaysia 1.522 0,3 (6,4) 447 Malaysia 1,562 (0.5) (7.6) 338 of the proceed invested to Grab Indonesia with the marking of close Singapore 3.088 (0,5) 8,6 1 Singapore 3,173 (0.5) 3.4 908 ties with the Grab ecosystem to further enhance growth. Another Regional Regional group interest is SAME which will be further digitized for value China 3.477 1,5 0,1 108.209 China 2,885 0.3 15.7 28,889 additions. Entrance to digital banking is inevitable we believe due to Hong Kong 25.110 1,0 (7,8) 21.764 Hong Kong 26,391 (0.2) 2.1 9,093 vast potential even just to cater EMTK – Grab customers and Japan 27.770 1,0 1,2 3.516 Japan 23,380 (0.6) 16.8 10,278 partners.
    [Show full text]
  • Indonesia's New Health Regime
    Cover_final_front.pdf 9/21/2010 1:31:39 PM Paper size: 210mm x 270mm Old problems, fresh solutions: Indonesia’s new LONDON health regime 26 Red Lion Square London A report from WC1R 4HQ United Kingdom the Economist Intelligence Unit C Tel: (44.20) 7576 8000 M Fax: (44.20) 7576 8500 Y E-mail: [email protected] CM MY NEW YORK CY 750 Third Avenue CMY 5th Floor K New York, NY 10017, US Tel: (1.212) 554 06000 Fax: (1.212) 586 0248 E-mail: [email protected] HONG KONG 6001, Central Plaza 18 Harbour Road Wanchai Hong Kong Tel: (852) 2585 3888 Fax: (852) 2802 7638 E-mail: [email protected] GENEVA Boulevard des Tranchées 16 1206 Geneva Switzerland Tel: (41) 22 566 2470 Fax: (41) 22 346 93 47 E-mail: [email protected] Sponsored by Old problems, fresh solutions: Indonesia’s new health regime Contents Preface 3 Executive summary 4 1. Introduction 6 2. Inequality: A country divided 9 Low wealth = poor health 9 The need for change 10 3. Innovations in healthcare financing 12 Raising healthcare spending 13 4. Improving health services 15 Prevention preferable to cure 16 5. The innovation imperative 17 Case study 1: A breath of fresh air Frugal innovation saving babies in Vietnam 18 Case study 2: Delinking health from wealth Business model innovation transforming Indian healthcare 19 Case study 3: Dial D for doctor Telemedicine tackling rural doctor shortage in Bangladesh 20 Conclusion 21 © Economist Intelligence Unit 2010 1 Old problems, fresh solutions: Indonesia’s new health regime © 2010 The Economist Intelligence Unit.
    [Show full text]